Company Filing History:
2 out of 25 
2 out of 548 
Years Active: 2021-2025
Title: Innovations of Ryan Fischer in Cell Therapy
Introduction
Ryan Fischer, an innovative inventor based in Shawnee, Kansas, is making significant contributions to the field of cell therapy. With a total of two patents to his name, Fischer’s work focuses on engineered regulatory T cells and their applications in treating inflammation and immune disorders.
Latest Patents
Fischer's latest patents involve the development of cell therapy compositions comprising engineered human regulatory T cells (eTregs). These cells are distinguished by the ectopic overexpression of FOXP3 and Helios protein. The patents outline methods for producing these eTregs through the introduction of separate nucleic acid constructs that encode FOXP3 and Helios, resulting in a unique population denoted as FOXP3+Helios+ eTregs. Additionally, his inventions describe compositions including mixed populations of CD4+ and CD8+ Treg cells, each exhibiting the same ectopic overexpression. These innovations have promising therapeutic implications, particularly for conditions involving inflammation and disorders of the immune system.
Career Highlights
Ryan Fischer has had a notable career, marked by his experience working with esteemed institutions such as Children's Mercy Hospital and the University of Kansas. His role at these organizations has allowed him to further his research in cell therapy and contribute to advancements in biomedical sciences.
Collaborations
Throughout his journey, Fischer has collaborated with eminent individuals in the field, including Amara Seng and Thomas Yankee. These partnerships have fostered a collaborative spirit, enhancing the scope and impact of his inventions.
Conclusion
Ryan Fischer’s innovative work in the realm of engineered regulatory T cells showcases his commitment to advancing medical therapies. With two patents under his belt and a dynamic career trajectory, he is poised to make further contributions that may one day transform treatment paradigms in addressing immune system-related disorders.